Beam Therapeutics, founded in 2017, is a biotechnology company focused on developing precision genetic medicines using base editing technology. This proprietary approach enables precise, predictable, and efficient single-base changes in DNA without introducing double-stranded breaks, potentially reducing off-target effects compared to traditional CRISPR methods. Beam's diverse pipeline targets a range of serious diseases, aiming to provide lifelong cures by correcting disease-causing point mutations at their source. Headquartered in Cambridge, Massachusetts, with a manufacturing facility in Research Triangle Park, North Carolina, Beam is committed to advancing the field of genetic medicine and improving patient outcomes.